KGH researchers develop DNA Probe

KGH researchers develop DNA Probe that could help individualize treatment for patients with prostate cancer in future

A patent-pending DNA probe developed for commercialization by researchers at Kingston General Hospital aims to reduce unnecessary prostate cancer surgeries through tailored treatment - personalized medicine at its best.

With colleagues, Dr. Jeremy Squire, Research chair in Molecular Pathology at Kingston General Hospital, has developed a novel DNA probe that could help to identify with greater accuracy aggressive prostate cancers from those that are less so.

Read the story on the Council of Academic Hospitals of Ontario website:

Posted: 2013 July 24